Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression

Next Previous
Trial Profile

An open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine (Primary) ; Abacavir; Abacavir/dolutegravir/lamivudine; Atazanavir; Darunavir; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Emtricitabine; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate; Etravirine; Lamivudine/abacavir; Lopinavir/ritonavir; Nevirapine; Raltegravir; Rilpivirine; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms DOLAM

Most Recent Events

  • 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
  • 16 Feb 2022 Results assessing multiomics plasma profile, presented at the 29th Conference on Retroviruses and Opportunistic Infections.
  • 13 Oct 2020 Results (n=15) published in the Journal of Infectious Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top